We Can not wait to see what the FED does now, we may finally have some more insight into policy and hopefully the first rate increase of the year to s...
Both of our reports from last week moving and still in play!
Are Big Market Swings an Opportunity for Gains? Good day everyone, Our most recent report on IMMX resulted in a potential 18.5% benefit for our member...
We Are Kicking Off Our Rebound And Hot Sector Reports Tomorrow Near Market Open
Recent Earnings Reports Are Looking Good We Are Kicking Off Our Rebound And Hot Sector Reports Tomorrow Near Market Open Good day everyone, January 20...
Biotricity (NASDAQ: BTCY) Scores Another FDA Win with a 501-K Clearance for its Biotres Cardiac Monitoring Device
Biotricity (BTCY) Scores Another FDA Win with a 501-K Clearance for its Biotres Cardiac Monitoring Device Good day everyone, Biotricity, Inc. (NASDAQ:...
The Broader Market’s are in Correction Territory. We have a new Biotech company report that will be available tomorrow 01-24-22 at market open.
The Broader Market’s are in Correction Territory We have a new Biotech company report that will be available tomorrow 01-24-22 at market open. ...
This Recent IPO With Only 4.12M Shares In The Float Immix Biopharma (NASDAQ: IMMX) May Be Setting Up For A Short Squeeze…
Updated coverage 01-20-22 ImmixBio (IMMX) Announces Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles For I...
Flora Growth (FLGC) May be the Best NASDAQ Value in Cannabis Companies Right Now With Expanding Operations. This is a Must See Report.
Trading at 84% off analyst’s consensus target of $10.75/share Trading at 92% off its August high of $21.45/share Good day everyone and welcome to all ...
Having Two FDA Fast Tracked Clinical Trials is a Major Milestone for Genprex (GNPX), and May be a Value Driver in the Near Term. Fast Track Designation Explained Here.
Good day everyone, Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and ...
A New to the NASDAQ Company That Offers Great Potential with a Robust Biopharma Pipeline, Tiny Market Cap and an Approved Product Ready for Distribution
Good day everyone, We want to report on a company in the biopharma sector that is new to the NASDAQ. This clinical stage company has solid financial m...
Meet SciSparc Ltd. (NASDAQ: SPRC) the Cannabis biotech disruptor with potential pipeline revenues of about $490M and they already have an approved drug in Canada! Float approx. 2.3M shares.
We Love This Stock! SciSparc Ltd. (NASDAQ: SPRC) already has a fully approved commercial product CannAmide, approved by Health Canada. CannAmide™ is r...
